[ad_1]
How we profited from the power of the POWR ratings with a powerful pairs trade philosophy on VAL and HP.
Alfred Winslow Jones is widely credited with creating the first hedge fund, or more accurately “hedged fund”, in the late 1940s.He supposedly got the idea while researching a markets article for Fortune magazine.
The idea was pretty basic-create a
[ad_1]
As the Fed is expected to raise interest rates higher than expected, the revived recession fears will keep the stock market under pressure in the upcoming months. Thus, it could be wise to scoop up shares of high-quality businesses, such as Johnson & Johnson (JNJ), Humana Inc. (HUM), and AutoZone, Inc. (AZO), which look poised for long-term growth, even
[ad_1]
Despite the economic turmoil, retail sales remained steady, indicating that consumer spending is not slowing down. While other sectors continue to feel the pinch of interest rate hikes, the grocery/big-box retail industry has been holding up well due to the inelastic demand for its products. Therefore, investors shouldn’t hesitate to buy shares of fundamentally strong big box retailers, Walmart
[ad_1]
Blue-chip stock, The Coca-Cola Company (KO), presents a strong long-term investment case, given its strong fundamentals, reliable dividends, favorable analyst estimates, high profitability, and strong past growth. Therefore, it could be wise to buy this stock and never sell it. Read more….
The stock market is expected to go through further volatility in the upcoming months as the Fed
[ad_1]
Bill Gates has brewskis on the brain.
The billionaire acquired close to a billion-dollar stake in Heineken Holding NV, giving him 3.7% of the Dutch company’s shares.
The filing by the Netherlands’ Financial Markets Authority (AFM) said the Microsoft founder bought 10.8 million shares on February 17, worth about $939.87 million. The transaction happened the same day that Heineken’s
[ad_1]
Apellis Pharmaceuticals’ (APLS) stock has jumped more than 25% year-to-date based on FDA approval for treating geographic atrophy. Despite the breakthrough, the company’s ability to scale up production remains a concern. Moreover, its closest competitor is also close to getting approval. Given its poor financials, stretched valuation, and weak profitability, it could be wise to avoid the stock now.